INT87741

Context Info Confidence 0.60 First Reported 2000 Last Reported 2009 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 4.77 Pain Relevance 0.50

cytosol (Msr1) plasma membrane (Msr1)

Anatomy Link Frequency hearts 1 Msr1 (Mus musculus)

Pain Link Frequency Relevance Heat Somatostatin 4 100.00 Pain 5 98.24 tolerance 2 97.56 imagery 2 81.44 Morphine 4 75.00 Cancer pain 3 75.00 depression 1 59.04 ischemia 12 41.60 colic 1 25.00 Inflammation 5 5.00

Disease Link Frequency Relevance Heat Targeted Disruption 65 99.98 Diabetes Mellitus 152 99.50 Myeloid Leukemia 25 99.20 Cancer 3 99.08 Supranuclear Palsy 6 98.28 Pain 3 98.24 Pituitary Cancer 4 92.44 Thyroid Disease 3 88.24 Hypertension 3 84.68 Ataxia 19 75.56

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Fourteen studies compared oral sustained release morphine (MSR) preparations with immediate release morphine (MIR).

Localization (release) of MSR

1) Confidence 0.60 Published 2003 Journal Cochrane Database Syst Rev Section Body Doc Link 14583997 Disease Relevance 0.05 Pain Relevance 0

In diabetic Tg DN PPET RAGE, and Tg DN MSR RAGE mice hearts, concentrations of CML, furosine, and pentosidine were similar to those in diabetic wild-type hearts (Table 2).

Localization (hearts) of DN MSR in hearts associated with targeted disruption, myeloid leukemia and diabetes mellitus

2) Confidence 0.20 Published 2008 Journal Diabetes Section Body Doc Link PMC2453611 Disease Relevance 3.08 Pain Relevance 0

OBJECTIVE: To compare the efficacy, safety and pharmacokinetics of a newly developed controlled-release suppository (MSR) with MS Contin tablets (MSC) in cancer patients with pain.

Localization (release) of MSR associated with pain and cancer

3) Confidence 0.12 Published 2000 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 10952476 Disease Relevance 0.27 Pain Relevance 0.25

The present study was performed to evaluate the effects of a slow release formulation of the somatostatin analog lanreotide (SR-L) on both hormone secretion and tumor size and to assess the tolerance in a series of thyrotropinomas treated for 6 months.

Localization (release) of SR-L associated with cancer, tolerance and somatostatin

4) Confidence 0.05 Published 2000 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10770186 Disease Relevance 0.44 Pain Relevance 0.22

III) for six weeks made use of MRS as a noninvasive measure of indices of metabolic function.

Localization (use) of MRS

5) Confidence 0.05 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.93 Pain Relevance 0.03

General Comments

This test has worked.